Q2 2026 saw 16% revenue growth and 28% EBITA growth, with strong margins led by Assistive Tech and MedTech. The Biopsafe acquisition expanded MedTech, while Specialty Pharma improved margins and sales. Net debt/EBITDA remains low, supporting further M&A.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.